GRAIL
Über GRAIL, INC
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Grail Inc at Wolfe Research Healthcare Conference
18.11.2025
15:00
Konferenz-Präsentationen
Q4 2025 Grail Inc Earnings Release
19.01.2026
21:02
Veröffentlichungen von Geschäftszahlen
Q1 2026 Grail Inc Earnings Release
11.05.2026
10:59
Veröffentlichungen von Geschäftszahlen